Clinical trials in Genk – page 23

1 420 clinical trials in Genk, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Genk at a glance

1 420

clinical trials

Research sites1

Quick filters

1 420 trials in Genk

Open in trial search

Clear cell renal cell carcinoma

Recruiting

Study of Lutetium-177-PSMA treatment for patients with advanced clear cell kidney cancer who had progression after first or second line therapy

Registered drugNo placebo

Study of Lutetium-177-PSMA treatment for patients with advanced clear cell kidney cancer who had progression after first or second line therapy

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Lutetium (177LU) vipivotide tetraxetan
Sponsor:European Organisation For Research And Treatment Of Cancer

Contact Research Centre

Asthma

Recruiting

Study of PF-07275315 to evaluate its effectiveness and safety in adults with moderate-to-severe asthma who have high levels of eosinophils in their blood

Investigational

Study of PF-07275315 to evaluate its effectiveness and safety in adults with moderate-to-severe asthma who have high levels of eosinophils in their blood

Investigational

Belgium

Participants:18–64 years · 65+ years
Sponsor:Pfizer Inc.

Contact Research Centre

COVID-19

Recruiting

Study of ibuzatrelvir alone or combined with remdesivir in adults with COVID-19 who have severely compromised immune systems

Investigational

Study of ibuzatrelvir alone or combined with remdesivir in adults with COVID-19 who have severely compromised immune systems

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:Ibuzatrelvir
Sponsor:Pfizer Inc.

Contact Research Centre

Plasma cell myeloma

Recruiting

Study of ABBV-453 alone or with drug combination for adults with multiple myeloma: evaluation of safety and effectiveness

Registered drugNo placebo

Study of ABBV-453 alone or with drug combination for adults with multiple myeloma: evaluation of safety and effectiveness

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Daratumumab
Sponsor:Abbvie Deutschland GmbH & Co. KG

Contact Research Centre

Ovarian cancer

Recruiting

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Transitional cell carcinoma

Recruiting

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Triple negative breast cancer

Recruiting

Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression

Registered drugNo placebo

Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Fungal infection+3

Recruiting

Study of fosmanogepix compared to standard antifungal drugs for treating invasive mold infections in adults

Registered drugNo placebo

Study of fosmanogepix compared to standard antifungal drugs for treating invasive mold infections in adults

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Amphotericin B
Sponsor:Basilea Pharmaceutica International AG Allschwil

Contact Research Centre

Atrial fibrillation+1

Recruiting

Evaluation of a Single Measurement Strategy for Direct Oral Anticoagulants in Frail Older Patients with Atrial Fibrillation or Venous Thromboembolism

Registered drugNo placebo

Evaluation of a Single Measurement Strategy for Direct Oral Anticoagulants in Frail Older Patients with Atrial Fibrillation or Venous Thromboembolism

Registered drugNo placebo

The Netherlands

Participants:65+ years
Substances:Apixaban
Sponsor:University Hospital Maastricht

Contact Research Centre

Hormone-refractory prostate cancer+1

Recruiting

Study of Darolutamide and Testosterone for Patients with Advanced Prostate Cancer Resistant to Standard Hormone Therapy

Registered drugNo placebo

Study of Darolutamide and Testosterone for Patients with Advanced Prostate Cancer Resistant to Standard Hormone Therapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Abiraterone
Sponsor:Universitaet Muenster

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Registered drug

Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Azacitidine
Sponsor:Janssen Cilag International

Contact Research Centre

Cardiac failure

Recruiting

Evaluating the Effect of Vicadrostat and Empagliflozin Combination Compared to Empagliflozin Alone in Patients with Heart Failure and Reduced Left Ventricular Function

Registered drug

Evaluating the Effect of Vicadrostat and Empagliflozin Combination Compared to Empagliflozin Alone in Patients with Heart Failure and Reduced Left Ventricular Function

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:BI 690517
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Genk

What the registry says about research in the country

01 Respiratory Disease Trials

Extensive research focusing on respiratory syncytial virus (RSV) and influenza prevention in older adults. Studies evaluate innovative vaccine combinations and immune responses in participants over 60 years.

RSV and human metapneumovirus vaccines
High-dose Influenza vaccines
Vaccine co-administration studies

Multiple trials aim to enhance protection against respiratory infections in vulnerable populations.

02 Cardiovascular Research

Comprehensive studies addressing various aspects of heart disease and related conditions, including innovative treatments for hypertrophic cardiomyopathy and heart failure.

Acute Heart Failure treatments
Pulmonary Hypertension therapies
Cardiovascular disease prevention

Trials explore new therapeutic approaches for managing complex cardiac conditions.

03 Autoimmune Conditions

Clinical research examining treatments for various autoimmune disorders, including innovative therapies for rheumatoid arthritis and Sjögren's syndrome.

Psoriatic Arthritis treatments
Rheumatoid Arthritis therapies
Primary Sjögren's Disease interventions

Studies focus on improving treatment outcomes and quality of life for patients with autoimmune conditions.

Back to Belgium All countries